MYMD

MyMD Pharmaceuticals, Inc. [MYMD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MYMD Stock Summary

Top 10 Correlated ETFs

MYMD


Top 10 Correlated Stocks

MYMD


In the News

08:30 29 Mar 2024 MYMD

MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a confer.

09:40 29 Mar 2024 MYMD

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

BALTIMORE--( BUSINESS WIRE )--MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England. Results from preclinical and clinical studies showed that MYMD-1 was safe and well-tolerated in healthy subjects and significantly reduced inflammation in a mouse model compared to the widely used arthritis treatment etanercept (Enbrel®). These findings support the continued evaluation of MYMD-1® for autoimmune and inflammatory disorders.

07:00 29 Mar 2024 MYMD

What to Know About Buying Penny Stocks on July 11th

Here's what you need to know about trading penny stocks on July 11th The post What to Know About Buying Penny Stocks on July 11th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10:05 29 Mar 2024 MYMD

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Benchmark Company Discovery Conference Date: December 2, 2021 Format: 1-on-1 meetings (virtual) Registration: Click here Benzinga Global Small Cap Conference Dates: December 8-9, 2021 Format: Present

04:02 29 Mar 2024 MYMD

Week 44 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An Edge

Two new Breakout Stocks for Week 44 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +68.8% YTD despite a record high 24 weeks out 43 weeks this year in negative conditions above the 40 MG level.

10:30 29 Mar 2024 MYMD

MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. The conference is being held at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D.

11:00 29 Mar 2024 MYMD

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD's superior potency over CBD by factor of 8,000 times. Supera-CBD is MyMD's pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The study was conducted by Eurofins D

10:00 29 Mar 2024 MYMD

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1's function in delaying aging early in the fourth quarter of 2021. Interim efficacy analysis from this study is expected in the first quarter of 2022. The primary goal of this Phase 2 double-blind, placebo-controlled clinical trial is to ach

10:17 29 Mar 2024 MYMD

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma

BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,096,933 titled “Method of Treating Disorders Associated with Chronic Inflammation.” The '933 patent becomes the thirteenth patent protecting the Company's lead cand

02:30 29 Mar 2024 MYMD

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.” The patent protects the Company's drug candidate Supe

MYMD Financial details

Company Rating
Strong Buy
Market Cap
5.54M
Income
-4.24M
Revenue
0
Book val./share
0.36
Cash/share
0.19
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
-2.2
Forward P/E
-
PEG
0.27
P/S
-
P/B
0.58
P/C
12.58
P/FCF
-0.8
Quick Ratio
1.49
Current Ratio
1.71
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
1.58
EPS this Y
-54.12%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-56.03%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-160%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-75%
Inst Own
0.01%
Inst Trans
0%
ROA
-19%
ROE
-31%
ROC
-0.99%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-8%
Shs Outstand
2.09M
Shs Float
1.84M
-
-
-
-
Target Price
-
52W Range
2.65-70.5
52W High
-96.59%
52W Low
+19.5%
RSI
32
Rel Volume
0.57
Avg Volume
57.92K
Volume
32.9K
Perf Week
-16.72%
Perf Month
-24.13%
Perf Quarter
-80.93%
Perf Half Y
-84.38%
-
-
-
-
Beta
3.258
-
-
Volatility
0.1%, 0.4%
Prev Close
0%
Price
2.39
Change
-2.45%

MYMD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.64154.44000
Net income per share
-23.73-380.79-0.29-0.85-0.39
Operating cash flow per share
-18.63-301.08-0.13-0.56-0.32
Free cash flow per share
-18.78-301.08-0.13-0.6-0.32
Cash per share
11.93948.170.450.330.12
Book value per share
12.76916.19-0.140.680.38
Tangible book value per share
12.23914.39-0.140.380.11
Share holders equity per share
12.76916.19-0.140.680.38
Interest debt per share
096.990.140.020
Market cap
744.03M1.96M4.43B6.37B1.34B
Enterprise value
743.85M2.43M4.44B6.37B1.34B
P/E ratio
-68.58-0.5-415.18-213.06-88.64
Price to sales ratio
446.711.24000
POCF ratio
-87.35-0.64-950.77-326.19-109.17
PFCF ratio
-86.66-0.64-950.77-304.64-109.17
P/B Ratio
127.540.21-843.43269.2191.15
PTB ratio
127.540.21-843.43269.2191.15
EV to sales
446.61.54000
Enterprise value over EBITDA
-70.08-0.73-536.14-225.8-88.09
EV to operating cash flow
-87.33-0.79-951.62-326.17-109.12
EV to free cash flow
-86.64-0.79-951.62-304.62-109.12
Earnings yield
-0.01-1.9800-0.01
Free cash flow yield
-0.01-1.5700-0.01
Debt to equity
00.11-0.790.010.01
Debt to assets
00.096.110.010.01
Net debt to EBITDA
0.02-0.14-0.480.010.04
Current ratio
3.386.740.0612.181.95
Interest coverage
00-7.96-47.35178.9
Income quality
0.790.910.490.650.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.40000
Research and developement to revenue
0.640000
Intangibles to total assets
0.03000.420.6
Capex to operating cash flow
0.01000.070
Capex to revenue
-0.040000
Capex to depreciation
-0.290000
Stock based compensation to revenue
0.032.27000
Graham number
82.532.8K0.963.61.82
ROIC
-1.16-0.3217.87-1.2-1.01
Return on tangible assets
-1.43-0.36-15.78-2.09-2.15
Graham Net
8.54811.240.30.30.05
Working capital
4.7M8.78M-2.2M11.63M2.63M
Tangible asset value
5.59M9.34M-5.26M13.15M4.2M
Net current asset value
4.7M8.78M-5.78M11.5M2.56M
Invested capital
00.11-0.790.010.01
Average receivables
896.16K109.6K621.45K600K0
Average payables
837.68K642.94K1.2M1.33M1.61M
Average inventory
1.22M392.13K-653.08K-752.57K0
Days sales outstanding
38.649.92000
Days payables outstanding
162.912.95K22.33K00
Days of inventory on hand
138.87980.63-18.65K00
Receivables turnover
9.4536.78000
Payables turnover
2.240.120.0200
Inventory turnover
2.630.37-0.0200
ROE
-1.86-0.422.03-1.26-1.03
Capex per share
-0.1500-0.040

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.09-0.09-0.01-0.10.09
Operating cash flow per share
-0.1-0.06-0.1-0.1-0.07
Free cash flow per share
-0.1-0.06-0.1-0.1-0.07
Cash per share
0.180.120.390.290.19
Book value per share
0.470.380.350.270.36
Tangible book value per share
0.20.110.090.010.12
Share holders equity per share
0.470.380.350.270.36
Interest debt per share
00-0.0200
Market cap
3.06B1.34B2.05B1.82B798.3M
Enterprise value
3.06B1.34B2.05B1.82B798.09M
P/E ratio
-208.71-90.92-1.18K-108.9249.36
Price to sales ratio
00000
POCF ratio
-747.99-595.75-516.92-463.24-252.91
PFCF ratio
-747.99-595.75-516.92-463.24-252.91
P/B Ratio
166.8291.15146.57169.0449.56
PTB ratio
166.8291.15146.57169.0449.56
EV to sales
00000
Enterprise value over EBITDA
-827.25-357.92-563.52-251.48-68.86
EV to operating cash flow
-747.96-595.48-516.9-463.24-252.84
EV to free cash flow
-747.96-595.48-516.9-463.24-252.84
Earnings yield
00000.01
Free cash flow yield
00000
Debt to equity
0.010.010.010.010.01
Debt to assets
0.010.01000
Net debt to EBITDA
0.040.160.0200.02
Current ratio
4.541.9510.025.411.71
Interest coverage
-240.0860.912.400
Income quality
1.110.62.630.94-0.78
Dividend Yield
00000
Payout ratio
00-0.37-0.040
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.520.60.370.420.48
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
10.90.290.790.85
ROIC
-0.2-0.25-0.05-0.51-0.17
Return on tangible assets
-0.38-0.52-0.02-0.280.36
Graham Net
0.130.050.03-0.070.06
Working capital
6.3M2.63M14.66M10.71M4.04M
Tangible asset value
7.83M4.2M3.51M243.23K5.61M
Net current asset value
6.17M2.56M1.88M-1.36M4.02M
Invested capital
0.010.010.010.010.01
Average receivables
00000
Average payables
2.01M1.87M1.78M1.43M1.5M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.2-0.25-0.03-0.390.25
Capex per share
00000

MYMD Frequently Asked Questions

What is MyMD Pharmaceuticals, Inc. stock symbol ?

MyMD Pharmaceuticals, Inc. is a US stock , located in Baltimore of Md and trading under the symbol MYMD

What is MyMD Pharmaceuticals, Inc. stock quote today ?

MyMD Pharmaceuticals, Inc. stock price is $2.39 today.

Is MyMD Pharmaceuticals, Inc. stock public?

Yes, MyMD Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap